SCHEDULE: Rubric Capital Management Discloses 9.24% Stake in Kiniksa Pharmaceuticals
Beneficial Ownership Disclosure
Rubric Capital Management LP and David Rosen have disclosed a beneficial ownership of 9.24% of Kiniksa Pharmaceuticals International, plc's Class A Ordinary Shares.
Summary
- Rubric Capital Management LP and David Rosen are the reporting persons for this Schedule 13G Amendment No. 3 filing.
- They collectively beneficially own 3,909,806 Class A Ordinary Shares of Kiniksa Pharmaceuticals International, plc.
- This ownership represents 9.24% of the Class A Ordinary Shares outstanding.
- The percentage is calculated based on 42,336,227 Class A Ordinary Shares outstanding as of April 25, 2025, as reported in Kiniksa's Quarterly Report on Form 10-Q.
- The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- Rubric Capital Master Fund LP, an investment fund managed by Rubric Capital, has the right to receive or direct dividends and proceeds from the sale of more than 5% of the Class A Ordinary Shares.
Sentiment
Score: 5
Explanation: Neutral, as a Schedule 13G is a factual disclosure of ownership and does not inherently convey positive or negative sentiment about the company's performance or outlook.
Positives
- Significant institutional ownership by Rubric Capital Management LP, indicating a notable investment in Kiniksa Pharmaceuticals.
Future Outlook
No forward-looking statements or guidance are provided.
Management Comments
- The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.
Industry Context
This filing is a standard disclosure of a significant passive investment by an institutional fund in a pharmaceutical company. It does not provide information on broader industry trends or the competitive landscape.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, potentially signaling confidence from a major investor.
- Regulatory Authorities: Fulfills SEC disclosure requirements for beneficial ownership, ensuring market transparency.
Key Dates
| Date | Description |
|---|---|
| 2025-04-25 | Date as of which 42,336,227 Class A Ordinary Shares were outstanding, as reported in the Issuer's Form 10-Q. |
| 2025-06-30 | Date of event which requires filing of this statement. |
| 2025-07-09 | Date of signing of the Schedule 13G Amendment No. 3 by Rubric Capital Management LP and David Rosen. |
Keywords
Kiniksa Pharmaceuticals, Rubric Capital Management, David Rosen, Schedule 13G, Beneficial Ownership, Class A Ordinary Shares, Institutional Investor, SEC Filing, Equity Stake, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.